{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:22Z","timestamp":1791312922077,"version":"4.3.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BUM13"],"award-info":[{"award-number":["BUM13"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.neuropharm.2017.02.006","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T13:16:02Z","timestamp":1486732562000},"page":"182-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain"],"prefix":"10.1016","volume":"117","author":[{"given":"Kerstin","family":"R\u00f6mermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Fedrowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"T\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Erker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.02.006_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/dmd.112.049148","article-title":"Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in\u00a0vitro study","volume":"41","author":"Bankstahl","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1073858412438697","article-title":"The GABA excitatory\/inhibitory shift in brain maturation and neurological disorders","volume":"18","author":"Ben Ari","year":"2012","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2009.03.003","article-title":"Cation-chloride cotransporters and neuronal function","volume":"61","author":"Blaesse","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A\u00a0family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib6","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","article-title":"Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy","volume":"30","author":"Brandt","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib8","doi-asserted-by":"crossref","first-page":"e57148","DOI":"10.1371\/journal.pone.0057148","article-title":"Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures","volume":"8","author":"Cleary","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(24)36456-0","article-title":"Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system","volume":"280","author":"Deguchi","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/jphp.12341","article-title":"The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in\u00a0vivo microdialysis study in the rat","volume":"67","author":"Donovan","year":"2015","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2015.12.001","article-title":"In\u00a0vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide","volume":"770","author":"Donovan","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib14","first-page":"2968","article-title":"Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice","volume":"56","author":"Glascock","year":"2011","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib15","series-title":"Restricted Brain Distribution of Bumetanide Is Mediated by Active Efflux Transporters (Rat Oatp &OAT3) at the Blood-brain Barrier","author":"Goda","year":"2010"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib16","series-title":"Goodman & Gilmans's the Pharmacological Basis of Therapeutics","first-page":"959","article-title":"Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout","author":"Grosser","year":"2011"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1471-4159.1993.tb13648.x","article-title":"Ionic composition of cisternal CSF in acute respiratory acidosis: lack of effect of large dose bumetanide","volume":"61","author":"Javaheri","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneuro0883","article-title":"Roles of the cation-chloride cotransporters in neurological disease","volume":"4","author":"Kahle","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrn3819","article-title":"Cation-chloride cotransporters in neuronal development, plasticity and disease","volume":"15","author":"Kaila","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0022-3565(25)13107-8","article-title":"Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier","volume":"277","author":"Kakee","year":"1996","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-008-9532-4","article-title":"Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC\/MS\/MS method combined with novel in-silico peptide selection criteria","volume":"25","author":"Kamiie","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/jpet.103.049197","article-title":"Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier","volume":"306","author":"Kikuchi","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1056-8719(97)00105-6","article-title":"Intracerebroventricular injection-induced increase in plasma corticosterone levels in the mouse: a stress model","volume":"39","author":"Kim","year":"1998","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib26","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.addr.2004.07.007","article-title":"Efflux transport systems for organic anions and cations at the blood-CSF barrier","volume":"56","author":"Kusuhara","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1602\/neurorx.2.1.73","article-title":"Active efflux across the blood-brain barrier: role of the solute carrier family","volume":"2","author":"Kusuhara","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0160-5402(86)90038-0","article-title":"Intracerebroventricular injections in mice. Some methodological refinements","volume":"16","author":"Laursen","year":"1986","journal-title":"J.\u00a0Pharmacol. Methods"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib29","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib30","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1046\/j.1523-1755.2000.00007.x","article-title":"ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2","volume":"57","author":"Leier","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"L\u00f6scher","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib33","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.2174\/138161211797440212","article-title":"Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected","volume":"17","author":"L\u00f6scher","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","article-title":"Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments","volume":"69","author":"L\u00f6scher","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib35","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1111\/bph.13231","article-title":"Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of human NKCC2 variant A","volume":"172","author":"Lykke","year":"2015","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1528-1167.2008.01989.x","article-title":"Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema","volume":"50","author":"Marchi","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","article-title":"Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs","volume":"26","author":"Matsson","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/157018006776743170","article-title":"Interaction of probenecid with the Breast Cancer Resistance Protein Transporter (BCRP\/ABCG2)","volume":"3","author":"Merino","year":"2006","journal-title":"Lett. Drug. Des. Discov."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.110.036863","article-title":"Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice","volume":"39","author":"Miyajima","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-008-9035-6","article-title":"Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid","volume":"10","author":"Morris","year":"2008","journal-title":"AAPS. J."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib41","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1124\/dmd.105.005264","article-title":"Functional characterization of human monocarboxylate transporter 6 (SLC16A5)","volume":"33","author":"Murakami","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1248\/bpb.27.1489","article-title":"New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system","volume":"27","author":"Ohtsuki","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/dmd.109.029454","article-title":"Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier","volume":"38","author":"Ose","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(14)70303-5","article-title":"Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1\/2 trial","volume":"14","author":"Pressler","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","article-title":"Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy","volume":"47","author":"Rambeck","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00041552-199809000-00006","article-title":"Renal transport of organic anions","volume":"7","author":"Roch-Ramel","year":"1998","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3565(24)29667-1","article-title":"Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins","volume":"296","author":"Schwab","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib49","doi-asserted-by":"crossref","first-page":"e0152677","DOI":"10.1371\/journal.pone.0152677","article-title":"The interactions of P-Glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation","volume":"11","author":"Senarathna","year":"2016","journal-title":"PLoS. One"},{"key":"10.1016\/j.neuropharm.2017.02.006_bib50","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib51","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1097\/01.ASN.0000143473.64430.AC","article-title":"Contribution of multidrug resistance protein 2 (MRP2\/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter","volume":"15","author":"Smeets","year":"2004","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-3565(24)29383-6","article-title":"Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier","volume":"298","author":"Sugiyama","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-409X(02)00172-2","article-title":"Drug efflux transporters in the CNS","volume":"55","author":"Sun","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24124","article-title":"A\u00a0novel prodrug-based strategy to increase effects of bumetanide in epilepsy","volume":"75","author":"T\u00f6llner","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.11.019","article-title":"The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide","volume":"746","author":"T\u00f6llner","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ejn.12424","article-title":"Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy","volume":"39","author":"T\u00f6pfer","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib57","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","article-title":"Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter","volume":"24","author":"Uchida","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00228-009-0714-8","article-title":"Blood-brain barrier transporters and response to CNS-active drugs","volume":"65","author":"Urquhart","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib60","doi-asserted-by":"crossref","first-page":"F713","DOI":"10.1152\/ajprenal.2000.279.4.F713","article-title":"Multidrug resistance protein mrp2 mediates ATP-dependent transport of classic renal organic anion p-aminohippurate","volume":"279","author":"Van Aubel","year":"2000","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib61","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","article-title":"The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP","volume":"13","author":"Van Aubel","year":"2002","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib62","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"VanWert","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.693","article-title":"Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology","volume":"31","author":"VanWert","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib64","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib65","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs","volume":"61","author":"Wessler","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.neuropharm.2017.02.006_bib66","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab. Dispos."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:48:44Z","timestamp":1758437324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817300515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":66,"alternative-id":["S0028390817300515"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.02.006","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}